Delta4 AI

Executive Summary

Delta4 AI is a Vienna-based TechBio company leveraging artificial intelligence and systems biology to repurpose existing drugs with known safety profiles for new therapeutic indications. Founded in 2018, the company's proprietary platform, Hyper-C, systematically analyzes complex biological data to uncover novel drug-disease relationships, aiming to accelerate and de-risk drug development for complex and rare diseases. By focusing on approved or clinically tested compounds, Delta4 AI reduces the time and cost of bringing treatments to patients, addressing significant unmet medical needs. Delta4 AI's approach has the potential to unlock value in shelved or off-patent drugs, creating a streamlined path to clinic. While the company remains private with limited public information, its AI-driven platform positions it within the growing drug repurposing market. Near-term value drivers include validation through partnerships or preclinical data. The company's focus on rare and complex diseases aligns with regulatory incentives and high unmet need, offering a compelling but early-stage investment thesis.

Upcoming Catalysts (preview)

• Q4 2026Licensing or collaboration deal for a repurposed drug candidate50% success
• Q1 2027Series A funding round completion60% success
• Q2 2027Publication of preclinical proof-of-concept data for lead indication70% success